Emergent BioSolutions Expands Its Proprietary NARCAN Direct Online Distribution Network To Include KLOXXADO Nasal Spray 8 Mg

GAITHERSBURG, Md., July 02, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced the expansion of its proprietary NARCANDirect® online distribution network to include KLOXXADO® (naloxone HCl) Nasal Spray 8 mg. The platform provides qualified direct purchasers, including emergency medical services, law enforcement, fire departments, government agencies, schools/universities and community-based naloxone distribution programs with streamlined access to opioid overdose response products. This addition complements the existing availability of NARCAN® (naloxone HCl) Nasal Spray 4 mg, increasing access to naloxone across the United States.

In January 2025, Emergent acquired exclusive commercial rights to KLOXXADO® Nasal Spray in the U.S. and Canada in an effort to help save lives by increasing access and availability of life-saving naloxone. By distributing both NARCAN® Nasal Spray 4 mg and KLOXXADO® Nasal Spray 8 mg through Emergent's expansive distribution networks, key stakeholders and communities now have more options in responding to opioid emergencies. KLOXXADO® Nasal Spray is a higher dose prescription emergency treatment for a known or suspected opioid overdose. NARCAN® Nasal Spray is available across the U.S and Canada and continues to be a trusted 4 mg naloxone standard of care in the community setting.

Expanding naloxone tools through NARCANDirect® comes at a pivotal moment in the ongoing fight against the opioid epidemic as provisional data released in May from the Centers for Disease Control and Prevention (CDC) show that drug overdose deaths in 2024 decreased 27 percent, with opioid-related deaths dropping by 34 percent from 2023.1 Shortly after this initial report, the CDC reported new provisional data available as of June 1, 2025 that found overdose deaths increased by roughly 1,400 in a 12-month period from January 2024 to January 2025.2,3 This incremental increase demonstrates the persistent and evolving nature of the opioid crisis, further reinforcing the continued need for new tools and ongoing support to ensure widespread opioid emergency preparedness.

"Tremendous progress in the fight against the opioid epidemic has been made since NARCAN® Nasal Spray became available over the counter in 2023, but this most recent uptick in overdose deaths reaffirms that we cannot simply stay the course," says Paul Williams, senior vice president, head of products business, global government & public affairs at Emergent. "Adding KLOXXADO® to our NARCANDirect® distribution is an important step in broadening access to naloxone and saving more lives. We will continue to work with partners across sectors to adopt new approaches and make systemic changes to ensure businesses, communities and individuals nationwide are ready to rescue."

Emergent is also introducing Convenience Kits on NARCANDirect®, which will equip frontline responders and community programs with the requested components of one medical-grade CPR mask and one pair of nitrile examination gloves for overdose response, provided in a durable hard case with internal pockets. To access these new offerings, public interest customers should visit NARCANDirect.com. Consumers, patients and healthcare providers can visit KLOXXADO.com and NARCAN.com to learn how to be prepared in an opioid overdose emergency with life-saving intranasal naloxone.